Allergan Aesthetics' newest indication targets a high-margin, underserved anatomical zone.
Allergan Aesthetics has secured FDA approval for Skinvive by Juvéderm for improvement of neck appearance—a first-to-market indication for a hyaluronic acid filler in this zone. The product uses Juvéderm's proprietary crosslinking technology and is positioned as a smooth-gel formulation designed for the thinner, more mobile skin of the neck and décolletage.
This approval matters because neck rejuvenation has historically relied on off-label filler use, laser, or RF microneedling. A cleared, labeled indication removes prescriber hesitation and creates a new revenue stream with minimal market education—most practices already stock Juvéderm. The neck is a high-visibility zone with strong patient demand and minimal competitive pressure from other fillers in this specific indication.
First FDA-cleared filler indication for neck appearance—a high-margin zone with minimal competitive pressure.
For practices, the move signals AbbVie's strategy to expand Juvéderm's clinical footprint beyond lips and cheeks, likely with corresponding rebate incentives through the Allē loyalty program to drive volume adoption.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
